Theravance Biopharma has announced the appointment of Andrew Hindman as senior vice president and chief financial officer.
Andrew brings nearly 25 years of life science industry experience spanning a broad range of functional areas including corporate strategy, finance, business development, operations, public policy and marketing.
“Andrew’s wide-ranging experience across critical functional areas, combined with his strong track record of driving significant value creation at several well-known life science companies, make him a valuable addition to the Theravance Biopharma team,” said Rick E Winningham, chairman and chief executive officer of Theravance Biopharma.
He has held several senior executive level positions in the biopharmaceutical industry, most recently as chief business officer of Acorda Therapeutics. In this role, he led Acorda’s acquisitions of Civitas Therapeutics and Biotie Therapies, helping transform the business from a single product business to a specialty neurology biotechnology company.